Show simple item record

dc.contributor.authorSantos, F. N.
dc.contributor.authorBorja-Cabrera, G. P.
dc.contributor.authorMiyashiro, L. M.
dc.contributor.authorGrechi, J.
dc.contributor.authorReis, A. B.
dc.contributor.authorMoreira, M. A. B.
dc.contributor.authorMartins Filho, O. A.
dc.contributor.authorLuvizotto, M. C. R.
dc.contributor.authorMenz, I.
dc.contributor.authorPessoa, L. M.
dc.contributor.authorGoncalves, P. R.
dc.contributor.authorPalatnik, M.
dc.contributor.authorPalatnik-de-Sousa, C. B.
dc.date.accessioned2014-02-26T16:59:53Z
dc.date.accessioned2014-05-20T13:44:33Z
dc.date.available2014-02-26T16:59:53Z
dc.date.available2014-05-20T13:44:33Z
dc.date.issued2007-08-14
dc.identifierhttp://dx.doi.org/10.1016/j.vaccine.2007.06.005
dc.identifier.citationVaccine. Oxford: Elsevier B.V., v. 25, n. 33, p. 6176-6190, 2007.
dc.identifier.issn0264-410X
dc.identifier.urihttp://hdl.handle.net/11449/15623
dc.description.abstractIn order to assess the immunotherapeutic potential on canine visceral leishmaniasis of the Leishmune (R) vaccine, formulated with an increased adjuvant concentration (1 mg of saponin rather than 0.5 mg), 24 mongrel dogs were infected with Leishmania (L.) chagasi. The enriched-Leishmune (R) vaccine was injected on month 6, 7 and 8 after infection, when animals were seropositive and symptomatic. The control group were injected with a saline solution. Leishmune (R)-treated dogs showed significantly higher levels of anti-FML IgG antibodies (ANOVA; p < 0.0001), a higher and stable IgG2 and a decreasing IgG I response, pointing to a TH1 T cell mediated response. The vaccine had the following effects: it led to more positive delayed type hypersensitivity reactions against Leishmania lysate in vaccinated dogs (75%) than in controls (50%), to a decreased average of CD4+ Leishmania-specific lymphocytes in saline controls (32.13%) that fell outside the 95% confidence interval of the vaccinees (41.62%, CI95% 43.93-49.80) and an increased average of the clinical scores from the saline controls (17.83) that falls outside the 95% confidence interval for the Leishmune (R) immumotherapy-treated dogs (15.75, CI95% 13.97-17.53). All dogs that received the vaccine were clustered, and showed lower clinical scores and normal CD4+ counts, whereas 42% of the untreated dogs showed very diminished CD4+ and higher clinical score. The increase in clinical signs of the saline treated group was correlated with an increase in anti-FML antibodies (p < 0.0001), the parasitological evidence (p = 0.038) and a decrease in Leishinania-specific CD4+ lymphocyte proportions (p = 0.035). These results confirm the immunotherapeutic potential of the enriched-Leishmune (R) vaccine. The vaccine reduced the clinical symptoms and evidence of parasite, modulating the outcome of the infection and the dog's potential infectiosity to phlebotomines. The enriched-Leishmune (R) vaccine was subjected to a safety analysis and found to be well tolerated and safe. (c) 2007 Elsevier Ltd. All rights reserved.en
dc.format.extent6176-6190
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofVaccine
dc.sourceWeb of Science
dc.subjectFML-vaccinept
dc.subjectimmunotherapypt
dc.subjectLeishmune((R)) vaccinept
dc.subjectcanine visceral leishmaniasispt
dc.subjectLeishmania chagasipt
dc.subjectkala-azarpt
dc.subjectsaponinpt
dc.subjectQuillaja saponaria molinapt
dc.subjectQS21pt
dc.titleImmunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune((R)) vaccineen
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dcterms.rightsHolderElsevier B.V.
dc.contributor.institutionUniversidade Federal do Rio de Janeiro (UFRJ)
dc.contributor.institutionUniversidade Federal de Ouro Preto (UFOP)
dc.contributor.institutionUniv Anhembi Morumbi
dc.contributor.institutionFiocruz MS
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionFort Dodge Saúde Anim Ltda
dc.description.affiliationUniv Fed Rio de Janeiro, Ctr Ciências Saude, Inst Microbiol Prof Paulo Goes, BR-21941590 Rio de Janeiro, Brazil
dc.description.affiliationUniv Fed Ouro Preto, Lab Imunopatol Nucl Pesquisas Ciências Biol, BR-35400000 Ouro Preto, MG, Brazil
dc.description.affiliationUniv Anhembi Morumbi, BR-03164000 São Paulo, Brazil
dc.description.affiliationFiocruz MS, Ctr Pesquisas Renee Rachou, BR-30190002 Belo Horizonte, MG, Brazil
dc.description.affiliationUNESP, Fac Med Vet, Dept Patol, BR-16050680 Aracatuba, SP, Brazil
dc.description.affiliationUniv Fed Rio de Janeiro, Fac Med, Hosp Univ Clementino Fraga Filho, BR-21941590 Rio de Janeiro, Brazil
dc.description.affiliationFort Dodge Saúde Anim Ltda, BR-13064798 Campinas, SP, Brazil
dc.description.affiliationUniv Fed Rio de Janeiro, Inst Biol, BR-21944970 Rio de Janeiro, Brazil
dc.description.affiliationUnespUNESP, Fac Med Vet, Dept Patol, BR-16050680 Aracatuba, SP, Brazil
dc.identifier.doi10.1016/j.vaccine.2007.06.005
dc.identifier.wosWOS:000248905900006
dc.rights.accessRightsAcesso restrito
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Odontologia, Araçatubapt
unesp.author.orcid0000-0002-6996-6896[2]
unesp.author.orcid0000-0002-4923-2334[11]
dc.relation.ispartofjcr3.285
Localize o texto completo

Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record